All In Biotech

BLA 761040 · Wyeth Pharms INC

Besponsa

Inotuzumab Ozogamicin · CD22-directed Immunoconjugate

NovelBreakthrough therapyPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Mar 6, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Aug 17, 2017

Approved uses

2

Original approval plus efficacy supplements

Registered trials

70

9 Phase 3, 21 recruiting

FAERS reports

2,992

2,854 serious, 1,018 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: HEPATOTOXICITY, INCLUDING HEPATIC VENO-OCCLUSIVE DISEASE (VOD) (ALSO KNOWN AS SINUSOIDAL OBSTRUCTION SYNDROME) and INCREASED RISK OF POST-HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) NON-RELAPSE MORTALITY WARNING: HEPATOTOXICITY, INCLUDING HEPATIC VENO-OCCLUSIVE DISEASE (VOD) (ALSO KNOWN AS SINUSOIDAL OBSTRUCTION SYNDROME) and INCREASED RISK OF POST- HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) NON-RELAPSE MORTALITY See full prescribing information for complete boxed warning. • Hepatotoxicity, including fatal and life-threatening VOD occurred in patients who received BESPONSA. ( 5.1 ) • A higher post-HSCT non-relapse mortality rate occurred in patients receiving BESPONSA ( 5.2 ) HEPATOTOXICITY, INCLUDING VOD • Hepatotoxicity, including fatal and life-threatening VOD occurred in patients with relapsed or refractory acute lymphoblastic leukemia (ALL) who received BESPONSA. The risk of...

What it is approved for

From the label in effect Feb 6, 2026.

1. INDICATIONS AND USAGE BESPONSA is indicated for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1 year and older . BESPONSA is a CD22-directed antibody and cytotoxic drug conjugate indicated for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1 year and older. ( 1 )

Mechanism: Inotuzumab ozogamicin is a CD22-directed antibody drug conjugate (ADC). Inotuzumab recognizes human CD22. The small molecule, N-acetyl-gamma-calicheamicin, is a cytotoxic agent that is covalently attached to the antibody via a linker. Nonclinical data suggest that the anticancer activity of inotuzumab ozogamicin is due to the binding of the ADC to CD22-expressing tumor cells, followed by internalization of the ADC-CD22 complex, and the intracellular release of N-acetyl-gamma-calicheamicin dimethylhydrazide via hydrolytic cleavage of the linker. Activation of N-acetyl-gamma-calicheamicin...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 6, 2024 Supplement 3 · Efficacy · priority review OrphanLabelLetter
  • Aug 17, 2017 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
1 products under this application
  • BESPONSA · INOTUZUMAB OZOGAMICIN 0.9/MG/VIAL · POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER, · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Inotuzumab Ozogamicin" as an intervention, any sponsor and status, largest first.

All 70 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death360
  • febrile neutropenia267
  • venoocclusive liver disease260
  • off label use232
  • pyrexia198
  • neoplasm progression155
  • thrombocytopenia154
  • acute lymphocytic leukaemia recurrent148
  • drug ineffective143
  • cytokine release syndrome142
  • sepsis138
  • venoocclusive disease132

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20071
20085
20094
201013
201113
201229
201329
201464
201571
201678
201777
2018245
2019251
2020255
2021368
2022365
2023350
2024343
2025254
2026177

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Besponsa (Inotuzumab Ozogamicin) · HCPCS J9229

2024 spending

$20.7M

Beneficiaries

143

680 claims

Per beneficiary

$144,884

2024 ASP limit $2,599.50 per unit

View as table
YearSpending
2020$23,701,002
2021$16,830,601
2022$16,719,295
2023$19,346,167
2024$20,718,365

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 56 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.